Monograph Details
|
|
Endocrine System
> Diabetes
|
|
DIABETA |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonylurea (2nd generation). |
| Generic Name |
|
Glyburide 1.25mg, 2.5mg, 5mg; scored tabs. |
| Indications |
|
Adjunct to diet in type 2 diabetes. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 2.5–5mg daily with breakfast. Elderly or debilitated: initially 1.25mg daily. Increase by 2.5mg at weekly intervals if needed per blood glucose. Maintenance: 1.25–20mg daily in single or divided doses (consider divided doses above 10mg daily); max 20mg daily. |
| Contraindications |
|
Ketoacidosis. |
| Precautions |
|
Impaired renal or hepatic function. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Monitor urine and blood glucose. Discontinue if jaundice or persistent rash occurs. Malnourished. Elderly. Debilitated. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. Disulfiram-like reaction with alcohol (rare). Monitor for 2 wks if transferring from chlorpropamide. |
| Adverse Reactions |
|
Increased risk of cardiovascular mortality. Hypoglycemia, cholestatic jaundice, GI disturbances, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria. |
| How Supplied |
1.25mg—50
2.5mg—100, 500
5mg—100, 500, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
